Drug intelligence / Profile preview

LM011

Development stage: Preclinical
Lead developer: Leadermed Group

Overview

LM011 is a preclinical-stage therapeutic candidate being developed by LeaderMed Group in collaboration with Combiphar. The program is specifically focused on achieving scarless wound healing, an area of significant unmet need in dermatology and aesthetic medicine. While the specific molecular target and modality (e.g., small molecule or biologic) have not been publicly disclosed in the company's pipeline documentation, the drug is positioned to advance through preclinical studies to support future clinical development for skin repair and regenerative applications.

Targets

ARF1 (ADP-ribosylation factor 1)GEF/GAP (Ras GEF / GAP family)

Beyond the preview

Go deeper on LM011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LM011.

Explore the full profile